ImmunityBio Shareholders Urged to Act Quickly on Class Action Lawsuit by ClaimsFiler

ImmunityBio Shareholder Alert

The claims surrounding ImmunityBio, Inc. have intensified as ClaimsFiler, a shareholder information service, reaches out to investors suffering losses exceeding $100,000. Shareholders are reminded of the critical upcoming deadline to file lead plaintiff applications in a class action lawsuit against ImmunityBio. This class action is currently progressing in the United States District Court for the Central District of California.

Investors who purchased securities in ImmunityBio between January 19 and March 24, 2026, are particularly urged to take note of this important deadline set for May 26, 2026. Those eligible for participation need to act swiftly, as filing can significantly impact the outcome of potential compensations for losses incurred during the class period.

The backdrop of this legal action stems from serious allegations against ImmunityBio and its executives for purportedly failing to disclose crucial information that could influence their share price. Notably, the company's advertisement relating to a treatment—Anktiva—has drawn scrutiny after a letter from the U.S. Food and Drug Administration (FDA) was disclosed publicly. The FDA’s warning highlights potential violations regarding the misrepresentation of the treatment's capabilities, which allegedly suggested that Anktiva could cure and prevent all types of cancer.

On March 24, 2026, following the public release of this letter, ImmunityBio's stock suffered a significant blow, plummeting $1.98, or 21%, closing at $7.42 per share. This sharp decline has intensified investor concerns, further validating the need for affected shareholders to unite in holding the company accountable.

The lawsuit, registered as Douglas v. ImmunityBio, Inc. et al., No. 26-cv-03261, reflects the need for transparency and adherence to federal securities laws in corporate practices. The outcome of this case will not only affect the involved shareholders but could set a precedent on how corporate communications can influence investor trust and market stability.

For shareholders considering participation in this legal case, ClaimsFiler offers a platform to assist in the process. Investors can visit ClaimsFiler.com for guidance, or contact them toll-free at (844) 367-9658 for further support. Their goal is to empower retail investors in recovering their stake from potential securities class action settlements.

In summary, the current scenario surrounding ImmunityBio presents an urgent call for action among shareholders. With a firm deadline approaching, any investor who feels they have been negatively impacted during the stated timeframe should consider filing a lead plaintiff application. As they navigate this challenging period, awareness and timely action are crucial in reclaiming losses and ensuring corporate accountability.